Published in Arthritis Rheum on June 01, 1992
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus | NCT02725515
Myfortic Versus Azathioprine in Systemic Lupus Erythematosus | NCT00504244
Health-related Quality of Life Measure in Pediatric Lupus | NCT00280137
Yellow Fever Vaccine in Patients With Rheumatic Diseases | NCT03430388
Haematological Indices in Systemic Lupus Erythematosus | NCT04110184
A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity (2008) 5.89
Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol (2011) 3.83
Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum (2009) 2.58
Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med (2006) 2.53
A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol (2010) 2.36
Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest (2005) 2.36
The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum (2013) 2.29
EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis (2009) 2.20
Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum (2009) 2.20
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis (2010) 2.09
Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum (2002) 2.08
The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest (2010) 2.07
High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis (2006) 2.00
Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum (2010) 1.97
Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther (2010) 1.93
Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol (2014) 1.91
Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) (2010) 1.88
Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol (2011) 1.85
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis (2012) 1.85
Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest (1998) 1.80
Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood (2007) 1.79
Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol (1999) 1.78
Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum (2006) 1.76
Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity. J Clin Invest (1998) 1.74
Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort. Arthritis Rheum (2008) 1.71
A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol (2010) 1.70
Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis (2005) 1.67
Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum (2011) 1.65
Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum (2008) 1.63
Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol (2008) 1.61
Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther (2009) 1.61
Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest (1997) 1.58
A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum (2010) 1.57
B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest (1996) 1.56
The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) (2015) 1.54
Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J Immunol (2004) 1.54
Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol (2009) 1.52
Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis (2005) 1.51
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) (2009) 1.48
Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity. Ann Rheum Dis (2005) 1.48
Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol (2007) 1.47
Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc Imaging (2013) 1.47
Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2011) 1.46
Retinal disease in patients with systemic lupus erythematosus. Ann Rheum Dis (2000) 1.45
Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis (2003) 1.44
The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol (2010) 1.42
Placental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnancies. Lupus Sci Med (2016) 1.41
Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int (2008) 1.39
White matter abnormalities and working memory impairment in systemic lupus erythematosus. Cogn Behav Neurol (2013) 1.39
Antinucleosome in systemic lupus erythematosus. A study in a Brazilian population. Clin Rheumatol (2011) 1.39
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2012) 1.38
Prednisone, lupus activity, and permanent organ damage. J Rheumatol (2009) 1.38
The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest (1994) 1.37
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther (2006) 1.36
T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus? Arthritis Res Ther (2014) 1.34
Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol (2009) 1.34
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum (2008) 1.34
Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol (2008) 1.33
TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther (2010) 1.27
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2009) 1.27
Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol (2012) 1.27
The search for lupus biomarkers. Best Pract Res Clin Rheumatol (2009) 1.26
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) (2011) 1.25
Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol (2008) 1.24
Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis (2005) 1.24
Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol (2010) 1.21
Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants. BMC Immunol (2009) 1.20
Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells. Ann Rheum Dis (2005) 1.19
Abnormalities in circulating plasmacytoid dendritic cells in patients with systemic lupus erythematosus. Arthritis Res Ther (2010) 1.17
Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol (2009) 1.16
Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis (2001) 1.16
Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol (1994) 1.15
How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev (2008) 1.15
Why can't we find a new treatment for SLE? J Autoimmun (2009) 1.15
Expression of Th-17 and RORγt mRNA in Behçet's Disease. Med Sci Monit (2011) 1.13
The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther (2013) 1.13
Stimulatory and inhibitory killer Ig-like receptor molecules are expressed and functional on lupus T cells. J Immunol (2009) 1.13
Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis (2004) 1.13
Inhibition of aberrant circulating Tfh cell proportions by corticosteroids in patients with systemic lupus erythematosus. PLoS One (2012) 1.13
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant (2015) 1.12
Development of outcome measures for autoimmune dermatoses. Arch Dermatol Res (2007) 1.12
Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J (2015) 1.12
Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Ann Rheum Dis (2006) 1.12
Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: use in the differential diagnosis of hyperferritinemia. Arthritis Res Ther (2005) 1.11
Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One (2012) 1.11
Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS Pathog (2011) 1.10
Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther (2012) 1.10
IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity. J Transl Med (2014) 1.10
Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus (2009) 1.10
Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis (2005) 1.09
Defensins- and cathepsin G-ANCA in systemic lupus erythematosus. Rheumatol Int (2006) 1.09
Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol (2010) 1.09
Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis (2000) 1.08
Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 1.08
Neurocognitive impairment in childhood-onset systemic lupus erythematosus: measurement issues in diagnosis. Arthritis Care Res (Hoboken) (2011) 1.08
Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis (2005) 1.08
Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst (1993) 7.87
Detection and identification of Mycobacterium tuberculosis by DNA amplification. J Clin Microbiol (1990) 5.48
Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol (2000) 5.01
FACT, a factor that facilitates transcript elongation through nucleosomes. Cell (1998) 4.91
Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 3.61
The bimodal mortality pattern of systemic lupus erythematosus. Am J Med (1976) 3.47
Structure of Rhodopseudomonas sphaeroides R-26 reaction center. FEBS Lett (1986) 3.28
The detection of mycobacterial DNA sequences in uncultured clinical specimens with cloned Mycobacterium tuberculosis DNA as probes. Tubercle (1988) 2.94
Psoriatic arthritis precipitated by physical trauma. J Rheumatol (1990) 2.70
The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (1980) 2.64
Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum (1988) 2.62
Accelerated nodulosis, pleural effusion, and pericardial tamponade during methotrexate therapy. J Rheumatol (1994) 2.62
Studying outcomes and hospital utilization in the elderly. The advantages of a merged data base for Medicare and Veterans Affairs hospitals. Med Care (1992) 2.49
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.49
Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis (2004) 2.47
Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol (1996) 2.46
Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and noncoding sequences. Genes Dev (1990) 2.46
The functions of tryptophan residues in membrane proteins. Protein Eng (1992) 2.45
Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum (1997) 2.40
Cdc73p and Paf1p are found in a novel RNA polymerase II-containing complex distinct from the Srbp-containing holoenzyme. Mol Cell Biol (1997) 2.37
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med (1977) 2.09
Methotrexate in systemic lupus erythematosus. J Rheumatol (1994) 2.08
Application of thoracoscopy for lung metastases. Chest (1995) 2.08
Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum (2001) 2.04
Vitamin D insufficiency in a large female SLE cohort. Lupus (2009) 2.02
Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol (2000) 1.93
Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum (1992) 1.88
Treatment recommendations for psoriatic arthritis. Ann Rheum Dis (2008) 1.85
An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology (1969) 1.85
Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Res (1991) 1.79
In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood (2000) 1.76
Comparison of cytosolic and mitochondrial hepatic enzyme alterations in Reye's syndrome. Pediatr Res (1980) 1.75
Predictors of systemic embolism in patients with mitral stenosis. A prospective study. Ann Intern Med (1998) 1.74
A discussion of item response theory and its applications in health status assessment. Med Care (2000) 1.73
The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg (1990) 1.72
HLA antigens in psoriatic arthritis. J Rheumatol (1986) 1.69
The uneven landscape of newborn intensive care services: variation in the neonatology workforce. Eff Clin Pract (2001) 1.66
Pulmonary artery perforation after Kirschner wire migration: case report and review of the literature. J Trauma (1993) 1.64
Thoracic actinomycosis. Chest (1993) 1.62
Role of CD4+ T cells in pathogenesis associated with Leishmania amazonensis infection. J Immunol (1997) 1.62
Prenatal sonographic characteristics and Doppler blood flow study in a case of a large fetal mediastinal teratoma. Ultrasound Obstet Gynecol (1998) 1.62
Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus (2000) 1.59
The systemic effects of intra-articular corticosteroid. J Rheumatol (1974) 1.57
Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol (2000) 1.57
Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol (2001) 1.56
"I" ministernotomy for aortic valve replacement. Ann Thorac Surg (1999) 1.53
Venous syndromes and pulmonary embolism in systemic lupus erythematosus. Ann Rheum Dis (1980) 1.52
HLA-D region genes and rheumatoid arthritis (RA): importance of DR and DQ genes in conferring susceptibility to RA. Ann Rheum Dis (1992) 1.52
Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol (1995) 1.52
How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford) (2000) 1.52
Acute renal failure in non-fulminant hepatitis A. Nephrol Dial Transplant (1996) 1.50
Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol (1996) 1.50
An alternative technique in the management of bullous emphysema. Thoracoscopic endoloop ligation of bullae. Chest (1997) 1.49
Mechanism and role of divalent cation binding of bacteriorhodopsin. Biophys J (1986) 1.48
Radiation Therapy Oncology Group (RTOG) survival data on anaplastic astrocytomas of the brain: does a more aggressive form of treatment adversely impact survival? Int J Radiat Oncol Biol Phys (1989) 1.47
Association of a specific ERAP1/ARTS1 haplotype with disease susceptibility in ankylosing spondylitis. Arthritis Rheum (2009) 1.46
Left atrial ball thrombus in nonrheumatic atrial fibrillation diagnosed by transesophageal echocardiography. Am Heart J (1992) 1.46
Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis (2008) 1.45
Psoriatic arthritis and imaging. Ann Rheum Dis (2005) 1.44
The use of single photon emission computerized tomography in neuropsychiatric SLE: a pilot study. J Rheumatol (1995) 1.43
Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis (2005) 1.42
Morbidity in systemic lupus erythematosus. J Rheumatol Suppl (1987) 1.41
Aneurysm of a nonpatent ductus arteriosus in a neonate: CT findings. AJR Am J Roentgenol (1993) 1.41
Acute renal failure in a young man, 9 days after a 5-h persisting erection following Viagra: is there a causal relationship? Nephrol Dial Transplant (1999) 1.41
Video-assisted cardiac surgery. Preliminary experience in reoperative mitral valve surgery. Chest (1996) 1.40
Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol (2001) 1.40
HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene (1997) 1.39
Video-assisted thoracoscopic operation for interruption of patent ductus arteriosus in adults. Ann Thorac Surg (1997) 1.39
One-stage sternal stenting with homograft bone after cardiac operation in pediatric patients. Ann Thorac Surg (1998) 1.38
CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet (2003) 1.38
Lateral mobility of erythrocyte membrane proteins studied by the fluorescence photobleaching recovery technique. J Biochem (1981) 1.37
Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J Rheumatol (1994) 1.35
Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol (1997) 1.34
Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol (1992) 1.34
The lupus activity criteria count (LACC). J Rheumatol (1984) 1.34
The nature and outcome of infection in systemic lupus erythematosus. Lupus (2002) 1.34
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum (2008) 1.34
Dissection of the interferon gamma-MHC class II signal transduction pathway reveals that type I and type II interferon systems share common signalling component(s). EMBO J (1992) 1.32
Midline pineal tumors and suprasellar germinomas: highly curable by irradiation. Radiology (1978) 1.32
Korean Nationwide Surveillance of Antimicrobial Resistance of bacteria in 1997. Yonsei Med J (1998) 1.31
Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol (2000) 1.31
Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol (1990) 1.30
Systemic lupus erythematosus in males. Medicine (Baltimore) (1983) 1.29
Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol (1995) 1.29
Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med (1985) 1.28